DSM Sinochem Pharma wins patent infringement case over amoxicillin API

The Delhi High Court has granted permanent injunction against the manufacture and sale of Sinopharm Weiqida Pharmaceutical’s Amoxicillin active pharmaceutical ingredient in India

New Delhi: DSM Sinochem Pharmaceuticals (DSP), the leading global player in production and commercialization of sustainable, enzymatic antibiotics, next generation statins and anti-fungals, has been granted a permanent injunction against Sinopharm Weiqida Pharmaceutical for patent infringement in India.
According to DSP’s wholly owned subsidiaries, DSM Sinochem Pharmaceuticals Netherlands B.V. and DSM Pharmaceuticals India, the High Court of Delhi, India, has granted a permanent injunction against Sinopharm Weiqida Pharmaceutical Co. (“Weiqida”) for patent infringement of Indian Patent Number 247,301. This patent, which is owned by DSP, relates to amoxicillin trihydrate having a low free water content and processes for the manufacture thereof.
The permanent injunction prevents the manufacture, use, importation, offering for sale and sale of Weiqida’s amoxicillin trihydrate active pharmaceutical ingredient in India, as well as any drug product that utilizes the active pharmaceutical ingredient.
“DSP welcomes the Court’s decision,” said Karl Rotthier, CEO at DSP. “The lawsuit is intended to protect DSP’s world class intellectual property portfolio relating to our innovative, sustainable, and environmental friendly amoxicillin technology.  DSP will continue to rigorously enforce its IP assets worldwide as it continues to invest in its innovative R&D programs directed to enzymatic, sustainable antimicrobials and statins.”